---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-082705"
form_type: "8-K"
ticker: "CADL"
cik: "0001841387"
company_name: "Candel Therapeutics, Inc."
filed_at: "2025-06-06T23:59:59+00:00"
generated_at: "2026-05-19T18:34:49.698279+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Candel appoints Maha Radhakrishnan, M.D., to Board; BLA submission for CAN-2409 on track for Q4 2026

## Summary
- Board expanded from 9 to 10 directors; Radhakrishnan named to Class II, term expiring 2026.
- Appointment effective June 4, 2025; she receives option for 28,480 shares vesting over 3 years.
- Radhakrishnan previously Group SVP and Chief Medical Officer at Biogen (Jan 2020 – Mar 2024).
- Candel targets Q4 2026 Biologics License Application submission for CAN-2409 in prostate cancer.
- She also serves as Executive Partner at Sofinnova Investments since August 2024.

## SEC filing metadata
- accession: 0000950170-25-082705
- form_type: 8-K
- ticker: CADL
- cik: 0001841387
- company_name: Candel Therapeutics, Inc.
- filed_at: 2025-06-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1841387/000095017025082705/0000950170-25-082705-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1841387/000095017025082705/cadl-20250604.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-082705
- JSON: https://secwatch.observer/filing/0000950170-25-082705.json
- Plain text: https://secwatch.observer/filing/0000950170-25-082705.txt

## Key facts
- Executive change
  Maha Radhakrishnan, M.D. was appointed as Director at Candel Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: On June 4, 2025, the Board of Directors (the “Board”) of Candel Therapeutics, Inc. (the “Company”) increased the size of the Board from nine (9) to ten (10) directors and unanimously appointed Maha Radhakrishnan, M.D., to fill the newly created vacancy on the Board, effective June 4, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1841387/000095017025082705/0000950170-25-082705-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.